Rna Diagnostics is a cancer diagnostics company building a platform of predictive biomarkers to improve the lives of cancer patients. Founded in 2010, Rna Diagnostics’ platform technology is the RNA Disruption Assay™.
The RNA Disruption Assay™ (RDA™) will provide physicians with an evaluation of how individual patients are responding to cancer therapy. If the cancer drugs are likely to provide the patient with a benefit, the physician and patient can continue treatment with confidence. If the cancer drugs are not likely to benefit the patient, physicians may consider alternate treatments. For patients, this means avoiding harmful side effects and increasing the possibility of improved survival outcomes.